Marché mondial du traitement de la maladie de Behçet – Tendances et prévisions de l'industrie jusqu'en 2028

Analyse et perspectives du marché : marché mondial du traitement de la maladie de Neuro-Behçet

Le marché de la maladie de Behçet devrait connaître une croissance de 3,80 % au cours de la période de prévision de 2021 à 2028. Le rapport de recherche sur le marché de la maladie de Behçet de Data Bridge fournit une analyse et des informations sur les différents facteurs qui devraient prévaloir tout au long de la période de prévision tout en fournissant leurs impacts sur la croissance du marché. L'augmentation de l'incidence de la maladie de Behçet accélère la croissance du marché de la maladie de Behçet.

La maladie neuro-Behçet (NBD) est définie comme une combinaison de symptômes et/ou de signes neurologiques chez un patient atteint de la maladie de Behçet (MB). Les syndromes concernés comprennent le syndrome du tronc cérébral, les manifestations de type sclérose en plaques, les troubles du mouvement, le syndrome méningo-encéphalitique, le syndrome myélopathique, la thrombose des sinus veineux cérébraux (TSVC) et l'hypertension intracrânienne.

Les principaux facteurs qui devraient stimuler la croissance du marché de la maladie neuro-behçet au cours de la période de prévision sont l'évolution des facteurs environnementaux. En outre, l'adoption croissante d'un mode de vie malsain devrait encore propulser le marché de la maladie neuro-behçet. De plus, l'augmentation des applications de médicaments pour le traitement de la maladie de Behçet devrait encore amortir la croissance du marché de la maladie neuro-behçet. D'autre part, la disponibilité des médicaments pour la maladie neuro-behçet devrait encore entraver la croissance du marché de la maladie neuro-behçet au cours de la période de prévision.

In addition, the increase in the demand of novel therapy will further provide potential opportunities for the growth in the neuro-behçet’s disease market in the coming years. However, the scientific and technological obstructions to increase the novel treatment in low income countries which might further challenge the growth of the neuro-behçet’s disease market in the near future.

The neuro-behçet’s disease market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the neuro-behçet’s disease market scenario, contact Data bridge market research for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.

Global Neuro-Behçet’s Disease Treatment Market Scope and Market Size

The neuro-behçet’s disease market is segmented on the basis of symptoms, forms, treatment, route of administration and end use. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of symptoms, the neuro-behçet’s disease market is segmented into brainstem syndrome, multiple-sclerosis like presentations, movement disorders, meningoencephalitic syndrome, myelopathic syndrome, cerebral venous sinus thrombosis (CVST), and intracranial hypertension.
• On the basis of forms, the neuro-behçet’s disease market is segmented into parenchymal and a non-parenchymal. Parenchymal is further sub segmented into brainstem, hemispheric, spinal, and meningoencephalitic manifestations. Non-parenchymal is further sub segmented into CVST and arterial involvement.
• On the basis of treatment, the neuro-behçet’s disease market is segmented into corticosteroids, immunosuppressive agents, immunomodulators, phosphodiesterase 4 (PDE4) inhibitor, interleukin-1β blocker and others.
• On the basis of route of administration, the neuro-behçet’s disease market is segmented into oral, injectable.
• On the basis of end use, the neuro-behçet’s disease market is segmented into hospitals, homecare, specialty clinics, others.

Neuro-Behçet’s Disease Treatment Market Country Level Analysis

The neuro-behçet’s disease market is analyzed, and market size information is provided by country, symptoms, forms, treatment, route of administration and end use as referenced above.

The countries covered in the neuro-behçet’s disease market report are the U.S., Canada, and Mexico in North America, Peru, Brazil, Argentina, and the rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, rest of the Middle East and Africa (MEA) as a part of the Middle East and Africa (MEA).

North America dominates the neuro-behçet’s disease market due to the increase in the cases of behcet’s disease suffers. Furthermore, the widespread research and development activities to study and discover more appropriate treatment of the neuro-behçet’s disease will further boost the growth of the neuro-behçet’s disease market in the region during the forecast period. Asia-Pacific is projected to observe significant amount of growth in the neuro-behçet’s disease market due to the increase in the patients suffering from behcet’s disease. Moreover, the rise in the disposable income of the people is further anticipated to propel the growth of the neuro-behçet’s disease market in the region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The neuro-behçet’s disease market also provides you with detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to the market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Neuro-Behçet’s Disease Treatment Market Share Analysis

Le paysage concurrentiel du marché de la maladie de neuro-behçet fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais cliniques, les approbations de produits, les brevets, la largeur et l'étendue du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liées au marché de la maladie de neuro-behçet.

Certains des principaux acteurs opérant sur le marché de la maladie de Behçet sont Eisai Co., Ltd, AbbVie Inc, Amarillo Gear Company., XOMA, Mitsubishi Tanabe Pharma Corporation, CELGENE CORPORATION, Amneal Pharmaceuticals LLC, Annora Pharma Pvt, Novartis AG, Pfizer Inc., CELLTRION INC., F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited., Abbott, Les Laboratoires, Cell Medica Limited, Panacea Biotec Ltd., Coherus BioSciences, Servier, Lupin Pharmaceuticals Inc., entre autres.

SKU-67373